

October 28, 2020

To,
**SINGAPORE EXCHANGE SECURITIES
TRADING LIMITED**
11 North Buona Vista Drive,
#06-07 The Metropolis Tower 2,
Singapore – 138589

Dear Sirs,

Sub: Information under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

Pursuant to Regulation 30 read with Schedule III Part A Para A (7) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we have to inform you that Mr. Milind Sarwate (DIN: 00109854) was appointed as Non-Executive Independent Director of the Company for a term of Five Years commencing from October 29, 2015 to October 28, 2020. Mr. Milind Sarwate, has conveyed that due to his pre-occupation, he would be unable to continue as Director on the Board of the Company post completion of his term as Non-Executive Independent Director with effect from close of business hours on October 28, 2020. Hence, Mr. Milind Sarwate ceases to be a Director of the Company from close of business hours on October 28, 2020.

Please find enclosed the requisite information as required under SEBI Circular No. CIR/CFD/CMD/4/2015 dated 9th September, 2015 in Annexure, content of which is self-explanatory.

You are requested to take the same on record.

Thanking You.

Yours faithfully,
For Glenmark Pharmaceuticals Ltd.

HARISH
VINAYAK KUBER

Digitally signed by HARISH
VINAYAK KUBER
Date: 2020.10.28 20:58:24
+05'30'

Harish Kuber
Company Secretary & Compliance Officer
Encl: As above

Glenmark Pharmaceuticals Ltd.

Glenmark House, B D Sawant Marg, Andheri (E), Mumbai 400 099

T: 91 22 4018 9999 F: 91 22 4018 9988 CIN No: L24299MH1977PLC019982 W: www.glenmarkpharma.com

Registered office: B/2, Mahalaxmi Chambers, 22 Bhulabhai Desai Road, Mumbai 400 026 E: complianceofficer@glenmarkpharma.com

Annexure

Disclosure of events and information pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 read with SEBI Circular No. CIR/CFD/CMD/4/2015 dated 9th September, 2015

Sr. No.	Particulars	Details
1.	Name of Director	Mr. Milind Sarwate (DIN: 00109854)
2.	Reason for change viz. appointment, resignation, removal, death or otherwise	Cessation of Directorship: Mr. Milind Sarwate was appointed as Non-Executive Independent Director of the Company for a term of Five Years commencing from October 29, 2015 to October 28, 2020. He conveyed that due to his pre-occupation, he would be unable to continue as Director on the Board of the Company post completion of his term as Non-Executive Independent Director with effect from close of business hours on October 28, 2020. Hence, he ceases to be a Director of the Company from close of business hours on October 28, 2020.
3.	Date of Cessation	Date of Cessation - From close of business hours on October 28, 2020
4.	Brief Profile (in case of appointment)	Not Applicable
5.	Disclosure of relationships between directors (in case of appointment of a director)	Not Applicable

Glenmark Pharmaceuticals Ltd.

Glenmark House, B D Sawant Marg, Andheri (E), Mumbai 400 099

T: 91 22 4018 9999 F: 91 22 4018 9988 CIN No: L24299MH1977PLC019982 W: www.glenmarkpharma.com

Registered office: B/2, Mahalaxmi Chambers, 22 Bhulabhai Desai Road, Mumbai 400 026 E: complianceofficer@glenmarkpharma.com